Biological immortality is not enough for an immerging community of Transhumanists. They’re hoping for a different take on Mind Uploading to offer them immortality. The Digital Immortality Definition depends on the person you ask, but one things is for certain the future is going to be weird when it comes to people longing for longevity and the goal of stopping aging completely. Living inside a computer by mind uploading to live forever may actually become a reality very soon in 2021. –
If you enjoyed this video, please consider rating this video and subscribing to our channel for more frequent uploads. Thank you! smile – TIMESTAMPS: 00:00 A new kind of Immortality. 02:05 Artificial Intelligence + Longevity =? 04:20 What are “Virtual Humans”? 06:40 The potential problem of consciousness. 08:53 Last Words. – #ai #longevity #immortality
Professor Stefan Lorenz Sorgner talks about his new book, ‘We Have Always Been Cyborgs’. Find out more about the book: https://bristoluniversitypress.co.uk/we-have-always-been-cyborgs.
“With an encyclopaedic knowledge of transhumanism and a deep philosophical grounding, especially in Nietzschean thought, Stefan Sorgner tackles some of the most challenging ethical issues currently discussed, including gene editing, digital data collection, and life extension, with uncommon good sense and incisive conclusions. This study is one of the most detailed and comprehensive analyses available today. Highly recommended for anyone interested in transhumanist/posthumanist ideas and in these issues generally.” N. Katherine Hayles, University of California, Los Angeles.
“An eye-opening, wide-ranging and all-inclusive study of transhumanism. Sorgner’s account avoids both the utopian trap and the bogeyman spectre. He makes a compelling case for placing ourselves on the transhuman spectrum. How we continue to use technologies is in our hands. Sorgner’s book is both a comprehensive introduction to transhumanist thought and a clear-sighted vision for its future realisation.” Julian Savulescu, University of Oxford.
Many people develop Alzheimer’s or other forms of dementia as they get older. However, others remain sharp well into old age, even if their brains show underlying signs of neurodegeneration.
Among these cognitively resilient people, researchers have identified education level and amount of time spent on intellectually stimulating activities as factors that help prevent dementia. A new study by MIT researchers shows that this kind of enrichment appears to activate a gene family called MEF2, which controls a genetic program in the brain that promotes resistance to cognitive decline.
The researchers observed this link between MEF2 and cognitive resilience in both humans and mice. The findings suggest that enhancing the activity of MEF2 or its targets might protect against age-related dementia.
Fighting The Battle Against Biological Aging — Dr. Eric Verdin MD, President & CEO, Buck Institute for Research on Aging.
Dr. Eric Verdin, MD (https://www.buckinstitute.org/lab/verdin-lab/) is President and Chief Executive Officer of the Buck Institute for Research on Aging, as well as Professor of Medicine at University of California, San Francisco (https://bms.ucsf.edu/people/eric-verdin-md).
Dr. Verdin’s lab currently studies the relationship between aging and the immune system per associated defects in the adaptive immune system, and over chronic activation of the innate immune system, as well as programs on how metabolism, diet, and small molecules regulate the activity of histone deacetylases and sirtuins, and thereby the aging process and its associated diseases, including Alzheimer’s.
Dr. Verdin has published more than 200 scientific papers and holds more than 15 patents. He is a highly cited scientist (top 1 percent) and has been recognized for his research with a Glenn Award for Research in Biological Mechanisms of Aging and a senior scholarship from the Ellison Medical Foundation.
Dr. Verdin is an elected member of several scientific organizations, including the American Association for the Advancement of Science, the American Society for Clinical Investigation, and the Association of American Physicians. He also serves on the advisory council of National Institute on Drug Abuse at the National Institutes of Health.
Dr. Verdin has extensive experience working with biotech companies. He is a founder of Acylin (purchased by Abbvie). He served on the scientific advisory boards of Elixir, Sirtris (purchased by GSK), Calico (Google), and Nokia, and he also served as advisor to Sofinnova Ventures.
Dr. Verdin has also worked for several years as a consultant to Novartis, GSK, J&J, Altana, Roche, Pfizer, and other biotech companies.
Dr. Verdin received his Doctorate of Medicine (MD) from the University of Liege, completed additional clinical and research training at Harvard Medical School, and has held faculty positions at the University of Brussels, the National Institutes of Health (NIH), and the Picower Institute for Medical Research.
British Daily Mirror article with SENS Science Writer Michael Rae discussing Alto’s labs, cellular reprogramming, and its place within the SENS platform.
I think this might be the answer to the question we’ve all been debating here lately. Provided it ACTUALLY happens, and that it includes others (like Jeff Bezos), and that it happens within a transparent, focused, well structured and effective framework.
It’s not the end all be all to wealth inequity, but it IS a good start and could really help us avoid another tribal political dust up and focus on a worthy, positive, and equitable posthuman (or whatever it is that make… See more.
The billionaire Elon Musk said he’d sell Tesla stock and donate the proceeds if the UN could prove that just a tiny percentage of his wealth could save tens of millions of lives.
Musk is the world’s richest man and recently became the first person in the Bloomberg Billionaires Index ever to have an estimated net worth north of $300 billion.
A few days ago, United Nations World Food Program (WFP) director David Beasley told CNN that a small group of ultra-wealthy individuals such as Tesla and SpaceX CEO Elon Musk could help solve world hunger with just a fraction of their net worth. Musk’s net worth currently stands at $311 billion thanks to a recent rally in TSLA stock, effectively making the CEO the world’s wealthiest individual today.
While speaking at CNN’s Connect the World with Becky Anderson, Beasley called for billionaires to “step up now, on a one-time basis.” He also noted that even just 2% of Musk’s current net worth could solve world hunger. This translates to roughly about $6 billion. “$6 billion to help 42 million people that are literally going to die if we don’t reach them. It’s not complicated,” the UN WFP director said.
Musk has now responded to Beasley’s statements. While responding to a post on Twitter which highlighted that the UN World Food Program actually raised $8.4 billion in 2,020 Musk noted that if the WFP could explain exactly how $6 billion would solve world hunger, then he would be more than willing to sell some TSLA stock right now. This is a key point as most of Musk’s net worth is tied to his majority stake in Tesla. This means that for Musk to have $6 billion in cash, he’d have to sell TSLA stock, which would then be taxed.
A commonly available oral diuretic pill approved by the U.S. Food and Drug Administration may be a potential candidate for an Alzheimer’s disease treatment for those who are at genetic risk, according to findings published in Nature Aging. The research included analysis showing that those who took bumetanide — a commonly used and potent diuretic — had a significantly lower prevalence of Alzheimer’s disease compared to those not taking the drug. The study, funded by the National Institute on Aging (NIA), part of the National Institutes of Health, advances a precision medicine approach for individuals at greater risk of the disease because of their genetic makeup.
The research team analyzed information in databases of brain tissue samples and FDA-approved drugs, performed mouse and human cell experiments, and explored human population studies to identify bumetanide as a leading drug candidate that may potentially be repurposed to treat Alzheimer’s.
“Though further tests and clinical trials are needed, this research underscores the value of big data-driven tactics combined with more traditional scientific approaches to identify existing FDA-approved drugs as candidates for drug repurposing to treat Alzheimer’s disease,” said NIA Director Richard J. Hodes, M.D.
While the Hubble Space Telescope ages, the James Webb Telescope prepares to launch.
With the aging Hubble space telescope experiencing another malfunction, how does the venerable telescope compare with its soon to the forthcoming James Webb?
